达比加群用于治疗血栓形成倾向患儿的静脉血栓栓塞症及二级预防
基于DIVERSITY试验和二级预防研究,评估达比加群在血栓形成倾向患儿中的疗效与安全性。DIVERSITY中血栓形成倾向亚组达比加群组主要终点发生率36% vs 标准治疗组22%(Mantel-Haenszel加权率差-0.135,95%CI -0.36至0.08,非劣效P=0.0014),与总人群结果一致;二级预防研究中12个月VTE复发率血栓形成倾向组2.8% vs 阴性/未知组0%。安全性与此前报道一致,探索性发现提示达比加群可能适用。
要点
- DIVERSITY试验血栓形成倾向亚组达比加群非劣效于标准治疗,主要终点36% vs 22%。
- 二级预防研究12个月VTE复发率血栓形成倾向组2.8% vs 阴性/未知组0%。
- 安全性与此前报道一致,探索性发现需谨慎解读。
核心结论
- 探索性发现提示达比加群可能为血栓形成倾向患儿合适的长期抗凝选择,但需谨慎解读。
研究设计与样本
- 基于2b/3期DIVERSITY试验(达比加群治疗3个月对比标准治疗)和单臂3期二级VTE预防研究(达比加群最长使用12个月)的分析。
主要发现
- DIVERSITY试验血栓形成倾向亚组中,达比加群组36%和标准治疗组22%达到主要终点(Mantel-Haenszel加权率差-0.135,95%CI -0.36至0.08,非劣效P=0.0014)。
- DIVERSITY总人群主要终点达比加群组46% vs 标准治疗组42%,显示达比加群非劣效于标准治疗。
- 血栓形成倾向亚组内,达比加群组VTE复发或index血栓进展的患者数数值上少于标准治疗组。
- 二级预防研究中,12个月VTE复发率血栓形成倾向组2.8% vs 阴性/未知血栓形成倾向组0%。
- 两项研究安全性与此前报道一致。
关键数值与推荐
- 血栓形成倾向类型在DIVERSITY试验(总人群)与二级预防研究中分别:factor V Leiden 42% vs 33%;凝血酶原突变(G20210A)19% vs 17%;抗凝血酶缺乏15% vs 20%;蛋白C/S缺乏23% vs 25%;抗磷脂抗体18% vs 20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些为探索性发现,应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with favorable safety. Dabigatran is approved by the European Medicines Agency and US Food and Drug Administration for pediatric indications. We assessed primary composite efficacy (complete thrombus resolution and freedom from VTE recurrence/VTE-related death) in subgroups with thrombophilia vs those with negative/unknown thrombophilia status in the DIVERSITY trial and safety in both studies. Thrombophilia types were similar between the DIVERSITY trial (total population) and secondary prevention studies: factor V Leiden, 42% vs 33%; prothrombin mutation (G20210A), 19% vs 17%; antithrombin deficiency, 15% vs 20%; protein C/S deficiency, 23% vs 25%; and antiphospholipid antibodies, 18% vs 20% of patients, respectively. In DIVERSITY, 36% and 22% of thrombophilia subgroup patients treated with dabigatran and SOC, respectively, met the primary end point (Mantel-Haenszel-weighted rate difference, -0.135; 95% confidence interval, -0.36 to 0.08; noninferiority P = .0014); comparable to the total DIVERSITY trial population (46% vs 42%) showing dabigatran noninferiority to SOC. Within this subgroup, numerically fewer patients experienced VTE recurrence or progression of index thrombus in the dabigatran treatment group vs SOC. In the secondary prevention study, VTE recurrence at 12 months occurred in 2.8% of patients with thrombophilia vs 0% with negative/unknown thrombophilia. Safety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia. These trials were registered at www.clinicaltrials.gov as #NCT01895777 and #NCT02197416.
引用
- Brandão LR, Tartakovsky I, Albisetti M, et al. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022. PMID: 36150047. doi:10.1182/bloodadvances.2021005681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。